New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
07:59 EDTNVAXNovavax price target raised to $10 from $4 at Ladenburg
Ladenburg believes that Novavax' balance sheet and opportunity to raise capital puts the company in position to fund both late-stage development and commercialization of its RSV vaccine in the U.S. Ladenburg thinks building a commercial organization is more attractive than partnering for the vaccine in the U.S. despite the higher risk and raised its price target on Novavax to $10 from $4.
News For NVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
09:21 EDTNVAXOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTNVAXNovavax granted FDA fast track designation to RSV F vaccine
Novavax announced that the FDA has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate, or RSV F vaccine, for protection of infants via maternal immunization.
November 17, 2014
16:10 EDTNVAXNovavax initiates Phase 2 clinical trial of quadrivalent seasonal influenza VLP
Subscribe for More Information
November 14, 2014
17:14 EDTNVAXNovavax initiates phase 2 clinical trial of RSV vaccine in elderly subjects
Subscribe for More Information
November 10, 2014
08:53 EDTNVAXNovavax initiates Phase 1 clinical trial of RSV F vaccine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use